Disease

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant

Retrieved on: 
Wednesday, July 6, 2022 - 7:00am
Diagnosis, C9orf72, Death, German Center for Neurodegenerative Diseases, Patient, Dementia, DPT, Influenza, Research, University, Brain, Bill & Melinda Gates Foundation, Man, Spinal cord, Paralysis, Union, Disease, ALS, Association, DZNE, Parkinson's disease, CDMO, Immune system, Infection, Motor neuron, Woman, Risk, Helmholtz Association, Neurodegeneration, Technology, Antibody, Nervous system, Neuron, Motor neuron disease, Human, Frontotemporal dementia, Pathology, Vaccine, Alzheimer's disease, Vaccination, Movement disorders, Mutation, WHO, Pharmaceutical industry, EU, Haemophilus influenzae

The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.

Key Points: 
  • The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.
  • About 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene, making it the most common genetic ALS variant.
  • DZNE developed an experimental vaccine that instructs the immune system to produce antibodies against these harmful poly-GA molecules.
  • Clinical trials for C9orf72 ALS, which is the most common genetic variant of ALS, are expected to commence in 2025.

Intravacc and DZNE awarded EU funding to develop vaccine against genetic ALS variant

Retrieved on: 
Wednesday, July 6, 2022 - 7:00am
Diagnosis, C9orf72, Death, German Center for Neurodegenerative Diseases, Patient, Dementia, DPT, Influenza, Research, University, Brain, Bill & Melinda Gates Foundation, Man, Spinal cord, Paralysis, Union, Disease, ALS, Association, DZNE, Parkinson's disease, CDMO, Immune system, Infection, Motor neuron, Woman, Risk, Helmholtz Association, Neurodegeneration, Technology, Antibody, Nervous system, Neuron, Motor neuron disease, Human, Frontotemporal dementia, Pathology, Vaccine, Alzheimer's disease, Vaccination, Movement disorders, Mutation, WHO, Pharmaceutical industry, EU, Haemophilus influenzae

The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.

Key Points: 
  • The project aims to develop the vaccine candidate identified at DZNE to the point where it can be clinically tested in humans.
  • About 5-10% of all ALS cases are caused by a mutation in the C9orf72 gene, making it the most common genetic ALS variant.
  • DZNE developed an experimental vaccine that instructs the immune system to produce antibodies against these harmful poly-GA molecules.
  • Clinical trials for C9orf72 ALS, which is the most common genetic variant of ALS, are expected to commence in 2025.

DGAP-News: Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance

Retrieved on: 
Wednesday, July 6, 2022 - 7:04am
Diagnosis, Science, Patient, LinkedIn, Biotechnology, CEO, Frankfurt Stock Exchange, Research, Animal Health, SRL Diagnostics, EVO, Boehringer, Death, AMR, ESG, Industry, Disease, ISIN, Public health, MDAX, Infection, Neurology, Therapy, Drug discovery, Software, Euronext Paris, Health, News, Executive Office of the President of the United States, NASDAQ, DGAP, Boehringer Ingelheim, Board, Twitter, Injury, Diabetes, Security (finance), Fine chemical, Medical device, Pharmaceutical industry, Vaccine, Evotec

We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMrieux, to combine our complementary strengths.

Key Points: 
  • We are excited to launch Aurobac together with our partners at Boehringer Ingelheim and bioMrieux, to combine our complementary strengths.
  • We supply the most comprehensive integrated diagnostic solutions to support an appropriate use of antibiotics (antimicrobial stewardship), said Alexandre Mrieux, bioMrieux Chairman and CEO.
  • Our role within the joint venture is to develop and commercialize diagnostic tests, including Companion Diagnostics, which deliver rapid, reliable and actionable results.
  • bioMrieux has over 55 years of diagnostics expertise with more than 75% of its research and development budget focused on antimicrobial resistance.

FDA Grants Priority Review to Genentech’s Mosunetuzumab for People With Relapsed or Refractory Follicular Lymphoma

Retrieved on: 
Wednesday, July 6, 2022 - 6:00am
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, Diagnosis, ROG, Fever, Liver, RO, Muscle weakness, Hypophosphatemia, Progression-free survival, Vomiting, Food, Headache, Dizziness, Lists of diseases, Fatigue, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Confusion, CD20, Lymphatic system, FDA, Patient, Pain scale, Weight loss, Lenalidomide, BTD, Mark (given name), Follicular lymphoma, B-cell lymphoma, AES, Pharmacokinetics, Cytokine release syndrome, Clinical trial, Diarrhea, Collection, DLBCL, Hoffmann-La Roche, European Commission, ASH, Walking, Rash, Urination, CD79B, AE, Neutropenia, CR, Infection, Cough, Nausea, Review, Priority review, ADC, Chills, Abdomen, Disease, Pain, Tumor lysis syndrome, Prognosis, Risk, CD3, NHL, Skin, Safety, Society, BLA, Pharmaceutical industry, Medical device, Vaccine, Polatuzumab vedotin, Genentech

The FDA is expected to make a decision on approval of this novel cancer immunotherapy by December 29, 2022.

Key Points: 
  • The FDA is expected to make a decision on approval of this novel cancer immunotherapy by December 29, 2022.
  • New therapeutic options are needed for follicular lymphoma, which often relapses after initial therapy and becomes increasingly difficult to treat each time it returns.
  • The GO29781 study [ NCT02500407 ] is a Phase I/II, multicenter, open-label, dose-escalation and expansion study evaluating the safety, efficacy and pharmacokinetics of mosunetuzumab in people with relapsed or refractory B-cell non-Hodgkins lymphoma.
  • Follicular lymphoma (FL) is the most common slow-growing (indolent) form of non-Hodgkins lymphoma, accounting for about one in five cases.

American Assets Trust, Inc. Announces Second Quarter 2022 Earnings Release Date and Conference Call Information

Retrieved on: 
Tuesday, July 5, 2022 - 9:21pm
Insurance, Personal Assets Trust, Epidemic, REIT, GLOBE, Conference call, Pandemic, COVID-19, Failure, Disease, Industry, U.S. Securities and Exchange Commission, Phrase, Annual report, Forward-looking statement, United, SAN, Environment, Real estate investment trust, NYSE, Lists of disasters, Form 10-K, Knowledge, Security (finance), Method, Conference, Property management

SAN DIEGO, July 05, 2022 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the Company) will announce its second quarter 2022 earnings in a press release to be issued after the market closes on Tuesday, July 26, 2022.

Key Points: 
  • SAN DIEGO, July 05, 2022 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the Company) will announce its second quarter 2022 earnings in a press release to be issued after the market closes on Tuesday, July 26, 2022.
  • Senior management will hold a conference call for its second quarter 2022 earnings on Wednesday, July 27, 2022 at 8:00 a.m. Pacific Time (PT).
  • Conference call access information is as follows:
    A live on-demand audio webcast of the conference call will be available on the Investor Relations section of the Companys website at www.americanassetstrust.com .
  • A replay webcast will be available on the Companys website approximately one hour after the conclusion of the conference call.

Spirit Realty Capital, Inc. Schedules Second Quarter 2022 Earnings Release and Conference Call

Retrieved on: 
Tuesday, July 5, 2022 - 9:10pm
Other Construction & Property, Residential Building & Real Estate, Construction & Property, REIT, Annual report, Epidemic, REIT, Accounting, Internal Revenue Code, Pandemic, COVID-19, Consumer, Company, Industry, Disease, U.S. Securities and Exchange Commission, Phrase, Forward-looking statement, Investment, Security (finance), Private Securities Litigation Reform Act, NYSE, Lists of disasters, Uncertainty, Nature, Interest, Internal Revenue Code section 1031, Coronavirus, Method, Real estate, Property management, Spirit

Spirit will host its second quarter earnings conference call and audio webcast on Thursday, August 4 at 9:30 a.m. Eastern Time.

Key Points: 
  • Spirit will host its second quarter earnings conference call and audio webcast on Thursday, August 4 at 9:30 a.m. Eastern Time.
  • Spirit Realty Capital, Inc. (NYSE: SRC) is a premier net-lease REIT that primarily invests in single-tenant, operationally essential real estate assets, subject to long-term leases.
  • More information about Spirit Realty Capital can be found on the investor relations page of the Company's website at www.spiritrealty.com .
  • Spirit does not guarantee that the events described will happen as described (or that they will happen at all).

Dr. Nancy Holekamp of the Pepose Vision Institute joins Vial as an Advisor to their Ophthalmology CRO

Retrieved on: 
Tuesday, July 5, 2022 - 9:30pm
Medical degree, Disease, Visual Science, Research, Ophthalmic, Retina, SAB, Volkmann's contracture, CRO, SAN, Traction, CTMS, Technology, George Washington University School of Medicine & Health Sciences, Vial, Gastroenterology, Washington University School of Law, Pi, Multimedia, Diabetic retinopathy, Fine chemical, Ophthalmology, Dermatology

SAN FRANCISCO, July 5, 2022 /PRNewswire/ -- Vial , a next-generation CRO, site network and technology platform, recently announced the planned launch of an Ophthalmology CRO .

Key Points: 
  • SAN FRANCISCO, July 5, 2022 /PRNewswire/ -- Vial , a next-generation CRO, site network and technology platform, recently announced the planned launch of an Ophthalmology CRO .
  • Vial is pleased to announce that Dr. Nancy Holekamp of the Pepose Vision Institute was brought on as an advisor.
  • Dr. Holekamp currently serves as the Director of Retina Services at the Pepose Vision Institute in St. Louis, MO.
  • Vial has executed on that vision by launching a next-generation CRO (live in Dermatology CRO , with slated launches in Ophthalmology CRO , Oncology CRO , Gastroenterology CRO ), a site network ( Dermatology Clinical Trials , Ophthalmology Clinical Trials , Gastroenterology Clinical Trials , Women's Health Clinical Trials , Neurology Clinical Trials ), and technology platform ( VialConnect CTMS ) to accelerate research.

BD Names Rishi Grover as Chief Integrated Supply Chain Officer

Retrieved on: 
Tuesday, July 5, 2022 - 9:15pm
Efficiency, United Technologies, Patient, LinkedIn, CEO, BDX, University of Chicago, Supply chain, Conroy, Business administration, EHS, National Institute, Sustainability, Electrical engineering, Industry, Disease, Company, Becton, Electricity, UTC Power, UTC Aerospace Systems, Electronics, Therapy, Retirement, Collins Aerospace, Carrier, 2025, Environment, University, NYSE, EVP, Organization, UTC, Massachusetts Institute of Technology, Health, Biophysical environment, Solution, Leadership, Safety, Twitter, BD, Management, Technology

FRANKLIN LAKES, N.J., July 5, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Rishi Grover has been named executive vice president (EVP) and chief integrated supply chain officer for BD, effective July 7, 2022.

Key Points: 
  • FRANKLIN LAKES, N.J., July 5, 2022 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that Rishi Grover has been named executive vice president (EVP) and chief integrated supply chain officer for BD, effective July 7, 2022.
  • In this role, he was responsible for all aspects of global operations, including lean manufacturing excellence, supply chain efficiency, operational transformation and EHS.
  • "Rishi has deep expertise in lean manufacturing and supply chain operations that will continue to ensure BD is at the forefront of our industry in navigating the current environment of unprecedented supply chain challenges while we build for the future," said Tom Polen, chairman, CEO and president of BD.
  • This experience will serve BD well as we advance our BD 2025 strategy and improve the speed and efficiency of our global supply chains."

Applied Molecular Transport to Report Top-line Phase 2 Results from MARKET Combination Trial of Oral AMT-101 in Patients with Moderate-to-Severe Ulcerative Colitis

Retrieved on: 
Tuesday, July 5, 2022 - 9:01pm
GLOBE, SAN, Patient, Ulcerative colitis, Disease, GMP, Nasdaq, Technology, IE, AMT, AMTI, CA, Q&A, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNF in biologic-nave patients with moderate-to-severe ulcerative colitis.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT) today announced that the company plans to report top-line data results from its Phase 2 MARKET combination trial of AMT-101 (GI- selective, oral fusion of IL-10) with anti-TNF in biologic-nave patients with moderate-to-severe ulcerative colitis.
  • A live webcast will be available on the Events page of the Applied Molecular Transport website at https://ir.appliedmt.com/news-events/events .
  • About Applied Molecular Transport Inc.
    AMT is a clinical-stage biopharmaceutical company developing novel oral biologic product candidates, by leveraging its technology platform to design biologic product candidates in patient friendly oral dosage forms.
  • Active transport is an efficient mechanism that utilizes the cells own machinery to transport materials across the IE barrier.

Weight Management Market Global Market Report 2022: Rise of Health Concerns like Obesity Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 5, 2022 - 5:01pm
Vitamins, Supplements, Other Health, Health, Fitness & Nutrition, Health Technology, People, Smoking, Overweight, Ageing, Allergy, Yoga, Adoption, Exercise, Intelligence, Disease, Industry, Non-governmental organization, Dietary supplement, Obesity, Awareness, CVD, Headache, Jogging, Literacy, Tobacco, Health, Degenerative disease, Habit, Urbanization, Artificial intelligence, AI, Nausea, WHO, Fast food, Milk

This market comprises various segments like special diets, equipment, and services that separately or combine help in the weight management of people.

Key Points: 
  • This market comprises various segments like special diets, equipment, and services that separately or combine help in the weight management of people.
  • People are becoming more conscious about their health and being, which is expected to drive the demand for the weight management market.
  • Besides that, growing concerns about the high rate of obesity and cardiovascular diseases have propelled people to opt for healthy practices, which holds a great opportunity for the weight management market.
  • Some of the restraints for the market include a high cost of equipment and special diets offered under weight management programs.